CCM Duopharma Makes Equity Invesment in SCM Lifescience of Korea for STEM Cell Technology and Development
INCHEON, SOUTH KOREA, October 25, 2018 – CCM Duopharma Biotech Berhad (“CCM Duopharma” or the “Company”) and SCM Lifescience Co., Ltd. (“SCM Lifescience”) of Korea today announced that they have entered into a share subscription agreement (“SSA”) whereby CCM Duopharma acquired common shares and redeemable preference convertible shares in SCM Lifescience upon and subject to the terms and conditions set out in the SSA.